tbuckley/cabot-search huggingface dataset:
P168 The ‘real world’ impact of the new BTS lung nodule surveillance guidelines: Abstract P168 Table 1
Authors: J Thomas, S Grundy
Journal: Thorax (2015)

<h3>Background and objectives</h3> The BTS published new guidelines for the investigation and management of pulmonary nodules in June 2015. These replace the Fleischner guidelines and are based on an improved evidence base produced predominantly from recent lung cancer screening trials. The BTS guidelines suggest no radiological follow-up for nodules smaller than 5 mm or &lt;80 mm<sup>3</sup> and limit CT follow-up to 12 months when volumetric analysis is used. The guidelines recommend use of the Brock Model (full with spiculation) to estimate the probability of malignancy in nodules ≥8 mm. The Brock group also published a parsimonious model which requires fewer clinical variables to calculate risk with almost equivalent accuracy. The objectives of this study are to establish the impact of the new guidance on the number of patients requiring radiological follow-up and the total number of scans recommended. We also studied any differences between the 2 Brock risk models. <h3>Methods</h3> We retrospectively reviewed 99 consecutive patients who were reviewed for indeterminate lung nodules. Their follow-up recommendations were calculated using 3 methods: 1) Fleischner, 2) BTS guidelines using Brock (full), 3) BTS guidelines using Brock (parsimonious). When using the Brock model we assumed worse case scenario if clinical information was not available (i.e. family history of lung cancer present). We assumed all nodules stayed stable in size and that volumetric analysis was performed. <h3>Results</h3> 23% fewer patients (75 vs. 99) required surveillance when using the BTS guidelines with Brock models rather than Fleischner. 38% fewer CT scans (132 vs. 214) would be performed in total when using Brock (full) compared with Fleischner. 31/99 patients had nodules ≥8 mm. Using the Brock (full) model 9/31 would have PET-CT compared with 6/31 with the Brock (parsimonious) model. <h3>Conclusion</h3> The new BTS guidelines will significantly reduce both the number of patients requiring radiological follow up for indeterminate nodules and also the total number of scans required overall. Even assuming worst case scenario in terms of clinical risk factors there is very little difference between Brock (full) and Brock (parsimonious). This needs assessing in a larger population with clinical outcomes evaluated.
Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapies.
Authors: Alexandra S. Bailey, SuChun Cheng, Eugene D. Kwon, Bradley C. Leibovich, Sabina Signoretti, Janice P. Dutcher, Leonard Joseph Appleman, Jeffrey Alan Sosman, Kim Allyson Margolin, Joseph Clark, Nikhil I. Khushalani, Brendan D. Curti, Marc S. Ernstoff, Allan J. Pantuck, Ulka N. Vaishampayan, Theodore Logan, David F. McDermott, Michael B. Atkins
Journal: Journal of Clinical Oncology (2013)

4521 Background: Expression of PDL1 by RCC has been associated with aggressive histology and poor survival. Tissue obtained from the patients enrolled in the IL-2 Select Trial, a prospective, single arm, multicenter CWG study, was analyzed by IHC to determine if PDL1or PDL3 expression predicted for response to initial or subsequent therapy. Methods: Paraffin embedded tumor tissue was stained for PDL1 and PDL3 expression, and results were correlated with RECIST defined response to IL2 treatment. Tumor tissue was considered positive for PDL1 if &gt;5% of the tumor membranes stained for the marker. A cutoff of 10% was used for PDL3. Duration of subsequent VEGFR/mTOR inhibitor therapy was also correlated with tissue PDL1/3 expression. Results: 120 eligible pts were enrolled; 115 had clear cell histology. The overall response rate (ORR) to IL2 was 25% (30/120) with a median OS of 40.6 months. 113 tumors were stained. 18 (16%) were PDL1+. ORR was 19% and 50% in the patients PDL1- and PDL1+ tumors, respectively (p=0.012). 85 (75%) tumors were PDL3+. ORR was 10.7% and 29.4% in the PDL3- and PDL3+ tumors, respectively (p=0.075). In the 17 patients who were positive for both PDL1 and PDL3, ORR was 52.9%. In the 27 pts who were negative for both PDL1 and PDL3, ORR was 11.1%. 69 patients received at least 1 dose of a VEGFR TKI as next therapy following IL2 treatment. 66 tumors were stained. Pts who were PDL1+/PDL3+ had a shorter duration on VEGFR TKI therapy compared to pts who were PDL1-/PDL3- (see Table). Conclusions: This small, retrospective analysis suggests that PDL1 and PDL3 tissue expression may predict for better response to IL2. PDL1 expression has been suggested as a possible predictor of response to anti-PD1 therapy. The current data suggests that its expression may predict for benefit to other immune therapies. PDL3 (+/- PDL1) expression appears to correlate to less benefit from subsequent VEGFR TKI therapy. Funded by NCI SPORE Grant # 5 P50 CA101942-08. [Table: see text]
Paroxetine, Cognitive Therapy or Their Combination in the Treatment of Social Anxiety Disorder with and without Avoidant Personality Disorder: A Randomized Clinical Trial
Authors: Hans M. Nordahl, Patrick A. Vogel, Gunnar Morken, Tore C. Stiles, Pål Sandvik, Adrian Wells
Journal: Psychotherapy and Psychosomatics (2016)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; The most efficacious treatments for social anxiety disorder (SAD) are the SSRIs and cognitive therapy (CT). Combined treatment is advocated for SAD but has not been evaluated in randomized trials using CT and SSRI. Our aim was to evaluate whether one treatment is more effective than the other and whether combined treatment is more effective than the single treatments. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; A total of 102 patients were randomly assigned to paroxetine, CT, the combination of CT and paroxetine, or pill placebo. The medication treatment lasted 26 weeks. Of the 102 patients, 54% fulfilled the criteria for an additional diagnosis of avoidant personality disorder. Outcomes were measured at posttreatment and 12-month follow-up assessments. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; CT was superior to paroxetine alone and to pill placebo at the end of treatment, but it was not superior to the combination treatment. At the 12-month follow-up, the CT group maintained benefits and was significantly better than placebo and paroxetine alone, whereas there were no significant differences among combination treatment, paroxetine alone, and placebo. Recovery rates at 12 months were much higher in the CT group (68%) compared to 40% in the combination group, 24% in the paroxetine group, and 4% in the pill placebo group. &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; CT was the most effective treatment for SAD at both posttreatment and follow-up compared to paroxetine and better than combined treatment at the 12-month follow-up on the Liebowitz Social Anxiety Scale. Combined treatment provided no advantage over single treatments; rather there was less effect of the combined treatment compared to CT alone.
Valve Thrombosis After Transcatheter Mitral Valve Replacement
Authors: Giuliana Capretti, Marina Urena, Dominique Himbert, Eric Brochet, Coppelia Goublaire, Constance Verdonk, Jose Luis Carrasco, Walid Ghodbane, David Messika-Zeitoun, Bernard Iung, Patrick Nataf, Alec Vahanian
Journal: Journal of the American College of Cardiology (2016)
High-Sensitivity Monitoring of Hematopoietic Chimerism after Double Umbilical Cord Blood Transplantation by Real-Time Quantitative Polymerase Chain Reaction.
Authors: Sophie Marty-Grès, Marielle Moussiere, Odile Avinens, Monique Andary, Annie Ramounau-Pigot, Patrice Ceballos, Jean-Côme Meniane, Geneviève Margueritte, Nathalie Fegueux, Jean-Francois Rossi, Jean-François Eliaou
Journal: Blood (2008)
The Use of PET Scans To Direct Immunotherapy Following Reduced Intensity Stem Cell Transplants in Adults with Lymphoid Malignancies.
Authors: Nichola Cooper, Irit Avivi, Peggs S. Karl, Dan Q. Hart, Kirsty Thomson, Adrian J.C. Bloor, Anthony H. Goldstone, David C. Linch, Peter Ell, J. Bomanji, Stephen Mackinnon
Journal: Blood (2005)
Recurrent DNA Mutations In Non-Hodgkin Lymphomas Reveal Candidate Therapeutic Targets
Authors: Andrew J Mungall, Ryan D Morin, Jianghong An, Oleksandr Yakovenko, Merrill Boyle, Nathalie A Johnson, Bruce Woolcock, Stephen Leach, Michael Mayo, Maria Mendez-Lago, Sarah Munro, Thomas Zeng, Yongjun Zhao, Martin Hirst, Robert A Holt, Richard Moore, Jacqueline E Schein, Randy D. Gascoyne, Douglas E Horsman, Joseph M. Connors, Steven J Jones, Marco A Marra
Journal: Blood (2010)
TCT-411 Results Of Percutaneous Coronary Intervention With Sequent Please® Paclitaxel Eluting Balloon Catheter In Diabetic Patients At A Very Long-Term Follow-Up
Authors: Ignacio Sanchez-Perez, Alfonso Jurado-Roman, Fernando Lozano, Maria T. Lopez-Lluva, Andrea Moreno-Arciniegas, Manuel Marina-Breysse, Natalia Pinilla-Echeverri
Journal: Journal of the American College of Cardiology (2015)
TCT-687 Cerebral protection device for transcatheter valve-in-valve procedures - the ALSTER data
Authors: Tobias Schmidt, Ulrich Schäfer, Ozan Akdag, Elena Ladich, Oscar D. Sanchez, Thielsen Thomas, Michael Schlüter, Dimitry Schewel, Jury Schewel, Felix Kreidel, Hannes Alessandrini, Karl-Heinz Kuck, Christian Frerker
Journal: Journal of the American College of Cardiology (2015)
The PI3K/mTOR Inhibitor NVP-BEZ235 Is a Promising Pre-Clinical Candidate for Therapeutic Intervention in Acute Myeloid Leukemia.
Authors: Nicolas Chapuis, Jerome Tamburini, Alexandre Macone, Alexa Samantha Green, Valérie Bardet, Lise Willems, Sophie Park, Norbert Ifrah, Francois Dreyfus, Sauveur-Michel Maira, Patrick Mayeux, Catherine Lacombe, Didier Bouscary
Journal: Blood (2009)
Deletion 5q in WHO-Defined Myeloproliferative Neoplasms: A Clinicopathological Description.
Authors: Rafael Santana-Davila, Ayalew Tefferi, Shernan G. Holtan, Rhett P. Ketterling, Ryan A. Knudson, David P. Steensma, Dong Chen, James D. Hoyer, Curtis A. Hanson
Journal: Blood (2007)
TCT-542 Stenting of Coronary Bifurcation Lesions with Bioresorbable Everolimus-Eluting Scaffolds. Poznan Bifurcation-Absorb Pilot Registry
Authors: Maciej Lesiak, Aleksander Araszkiewicz, Magdalena Lanocha, Marek Grygier, Malgorzata Pyda, Wlodzimierz Skorupski, Przemyslaw Mitkowski, Sylwia Iwanczyk, Michal B. Lesiak, Andrzej Siniawski, Stefan Grajek
Journal: Journal of the American College of Cardiology (2015)
Long term disease-free survival after stopping trastuzumab in trastuzumab-sensitive metastatic breast cancer patients treated with local-regional therapy
Authors: M. A. Cobleigh, K. L. Griem, K. P. Siziopikou
Journal: Journal of Clinical Oncology (2008)

11542 Background: The standard of care when treating patients with metastatic or locally recurrent HER2-positive breast cancer includes using T alone or in combination with chemotherapy. Patients whose disease responds to trastuzumab generally continue therapy until disease progression. Little is known about women with limited disease volume who respond to T and receive definitive local-regional treatment. Can T be stopped in these patients? At a cost upwards of $40,000/year and an FDA recommended weekly dosing interval, any information on this topic would be valuable. Methods: Case series of women seen by a single medical oncologist. Patients had HER2-positive metastatic or locally recurrent breast cancer whose disease was resectable or could be encompassed within a radiation therapy (RT) port. This is not a clinical trial. Patients were treated according to the best medical judgment of the physicians involved. Results: Six patients are described. Two patients had chest wall recurrence (skin) in a previously irradiated field. Both responded to single agent T and then received concurrent T + RT. Two patients experienced local-regional lymph node recurrence; one of these received single agent T, responded, then received concurrent T + RT. The other received T and chemotherapy, responded, and received concurrent T + RT. Two patients had solitary lung metastasis, one with mediastinal nodal involvement. Both received T and responded. One then received concurrent T + RT. The other underwent resection. Three women remain disease-free at 5, 5 and 8 years after stopping T. Three recurred 6, 5 and 8 years after stopping T; all responded to single agent T upon re-treatment. Conclusions: Patients with metastatic, HER2-positive, T-sensitive breast cancer whose disease is resectable or can be encompassed within a radiation therapy port can stop T and experience prolonged disease-free survival. Although this clinical situation is rare, the drug cost saved for these patients is estimated at 116 million dollars with 1,500 clinic visits eliminated. The favorable interaction of T and radiation is noteworthy and has been demonstrated in head and neck cancer with another inhibitor of the HER family, C225, in a randomized trial. No significant financial relationships to disclose.
Ultrastructural organisation of HCV from the bloodstream of infected patients revealed by electron microscopy after specific immunocapture
Authors: Eric Piver, Audrey Boyer, Julien Gaillard, Anne Bull, Elodie Beaumont, Philippe Roingeard, Jean-Christophe Meunier
Journal: Gut (2016)

HCV particles are associated with very low-density lipoprotein components in chronically infected patients. These hybrid particles, or 'lipo-viro particles' (LVPs), are rich in triglycerides, and contain the viral RNA, the capsid protein, E1E2 envelope glycoproteins and apolipoproteins B and E. However, their specific ultrastructural organisation has yet to be determined. We developed a strategy for the preparation of any viral sample that preserves the native structure of the LVPs, facilitating their precise morphological characterisation.Using a strategy based on the direct specific immunocapture of particles on transmission electron microscopy (TEM) grids, we characterised the precise morphology of the viral particle by TEM.The LVP consists of a broad nucleocapsid surrounding an electron-dense centre, presumably containing the HCV genome. The nucleocapsid is surrounded by an irregular, detergent-sensitive crescent probably composed of lipids. Lipid content may determine particle size. These particles carry HCV E1E2, ApoB and ApoE, as shown in our immuno-EM analysis. Our results also suggest that these putative LVPs circulate in the serum of patients as part of a mixed population, including lipoprotein-like particles and complete viral particles.Twenty-five years after the discovery of HCV, this study finally provides information about the precise morphological organisation of viral particles. It is truly remarkable that our TEM images fully confirm the ultrastructure of LVPs predicted by several authors, almost exclusively from the results of molecular biology studies.
Strong Antibody Responses Against a Unique Region of CT-Antigen SSX-2 Are Induced After Allogeneic Stem Cell Transplantation and Correlate with Clinical Remission In Patients with Multiple Myeloma
Authors: Sebastian Kobold, Tim Luetkens, Yanran Cao, Corinna Eberhardt, Sinje Tams, Britta Marlen Bartels, Katrin Bartels, Sabrina Meyer, Friedrich Haag, Carsten Bokemeyer, Axel R. Zander, Nicolaus Kröger, Djordje Atanackovic
Journal: Blood (2010)
Chronic Graft-Versus-Host Disease after Tacrolimus Versus Cyclosporine for Graft-Versus-Host Disease Prophylaxis in Pediatric Patients Undergoing Matched Unrelated Donor Hematopoietic Stem Cell Transplantation. A Pediatric Blood and Marrow Transplant Consortium Study..
Authors: Mark P. Atlas, Greg Yanik, Kirk R. Schultz, Rakesh K. Goyal
Journal: Blood (2007)
0utpatient and Home Chemotherapy: Preliminary Results of the Experience of the Limousin (France) Hematological Care Network.
Authors: Mohamed Touati, Liliane Remenieras, Stephane Moreau, eronique Truffinet, Sophie Lefort, Francoise ergnenegre, Mona Abouelfadel, Aline Lagarde, Agnes Cournede, Annick Daulange, Marie-Charlotte Laffetas, Dominique Bordessoule
Journal: Blood (2010)
Comparative Outcomes of Reduced-Intensity and Myeloablative Conditioning in Unrelated Cord Blood Transplantation for Adult Standard-Risk Hematological Diseases
Authors: Aya Nishida, Hikari Ota, Kazuya Ishiwata, Masanori Tsuji, Hisashi Yamamoto, Yuki Asano-Mori, Go Yamamoto, Naoyuki Uchida, Koji Izutsu, Atsushi Wake, Akiko Yoneyama, Shigeyoshi Makino, Shuichi Taniguchi
Journal: Blood (2012)
A framework for combining a motion atlas with non-motion information to learn clinically useful biomarkers: Application to cardiac resynchronisation therapy response prediction
Authors: Devis Peressutti, Matthew Sinclair, Wenjia Bai, Thomas Jackson, Jacobus Ruijsink, David Nordsletten, Liya Asner, Myrianthi Hadjicharalambous, Christopher A. Rinaldi, Daniel Rueckert, Andrew P. King
Journal: Medical Image Analysis (2016)

We present a framework for combining a cardiac motion atlas with non-motion data. The atlas represents cardiac cycle motion across a number of subjects in a common space based on rich motion descriptors capturing 3D displacement, velocity, strain and strain rate. The non-motion data are derived from a variety of sources such as imaging, electrocardiogram (ECG) and clinical reports. Once in the atlas space, we apply a novel supervised learning approach based on random projections and ensemble learning to learn the relationship between the atlas data and some desired clinical output. We apply our framework to the problem of predicting response to Cardiac Resynchronisation Therapy (CRT). Using a cohort of 34 patients selected for CRT using conventional criteria, results show that the combination of motion and non-motion data enables CRT response to be predicted with 91.2% accuracy (100% sensitivity and 62.5% specificity), which compares favourably with the current state-of-the-art in CRT response prediction.
“Share &amp; Meet” project: an innovative telemedicine solution for remotization of pathology and e-oncology
Authors: M. Botteghi, N. Masalu, R. Tumino, M. Puccetti, P. Serra, A. Colamartini, A. Zaccheroni, N. Caroli, I. Khangane, G. Melegari, M. Altini, D. Amadori
Journal: Annals of Oncology (2015)
Clinical Usefulness and Safety of Peripherally-Inserted Central Catethers (PICC) in Hematological Patients.
Authors: Giacomo Salvatore Morano, Caterina Mercanti, Vincenzo Federico, Angela Matturro, Alessandra Micozzi, Roberto Latagliata, Massimo Breccia, Corrado Girmenia, Gregorio Antonio Brunetti, Paola Berneschi, Massimo Giampaoletti, Robin Foà, Giuliana Alimena
Journal: Blood (2009)
GW27-e0047 Characteristics of Cardiopulmonary Exercise Tests in Patients with Borderline Pulmonary Arterial Pressure
Authors: Jiang Rong, Hui Liu, Bigyan Pudasaini, Lan Wang, Qin-Hua Zhao, Jing He, Jian Guo, Zhi-Cheng Jing, Jin-Ming Liu
Journal: Journal of the American College of Cardiology (2016)
TCT-380 Comparison Among Different Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Catheterization: A Hierarchical Bayesian Network Meta-Analysis of Randomized Trials
Authors: Daniele Giacoppo, Giuseppe Gargiulo, Sergio Buccheri, Patrizia Aruta, Piera Capranzano, Davide Capodanno, Corrado Tamburino
Journal: Journal of the American College of Cardiology (2015)
TCT-273 Influence Of Ticagrelor Versus Clopidogrel On Hemostatic Measurements, Vascular Function And Left Ventricular Remodeling In STEMI Patients
Authors: Young-Hoon Jeong, Kye-Hwan Kim, Min Gyu Kang, Jin-Sin Koh, Jeong-Rang Park, Yongwhi Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang
Journal: Journal of the American College of Cardiology (2015)
Quality and Safety in Health Care, Part XVII
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2016)

Mainly due to the positive effect on quality and safety from the Veterans Health Administration National Surgical Quality Improvement Program (VASQIP), a National Surgical Quality Improvement Program (NSQIP) for private hospitals was begun, which is now under the auspices of the American College of Surgeons (ACS). More than 600 hospitals now participate in the ACS-NSQIP. The information gained by the institutions is typically utilized to initiate quality improvement activities. The ACS-NSQIP also shares information on how to get better results, has national meetings, and provides other support.
TCT-489 Complete percutaneous revascularization in ischemic heart failure improves survival – report from the COMMIT-HF registry
Authors: Lukasz Pyka, Michal Hawranek, Mateusz Tajstra, Jarosław Gorol, Anna Kurek, Adam Krajewski, Andrzej Lekston, Marek Gierlotka, Mariusz Gasior
Journal: Journal of the American College of Cardiology (2015)
GW27-e1086 “Real world” implementation of novel oral antiplatelets in ST-elevation acute myocardial infarction acute coronary syndrome undergoing to primary percutaneous coronary intervention: CHUS registry
Authors: Alfredo Redondo Dieguez, Ana Belen Cid Alvarez, Ramiro Trillo Nouche, Carlos Galvao, Diego Lopez Otero, Raymundo Ocaranza, Monica Fernandez, Rocio Gonzalez Ferreiro, JR Gonzalez-Juanatey
Journal: Journal of the American College of Cardiology (2016)
Pindar’s Bestowal of Victory on a Dialysis Patient
Authors: Margaret Bobalek King
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT-729 Percutaneous left atrial appendage closure in patients with non-valvular atrial fibrillation with Watchman® left atrial appendage device: single center experience and results up to three years follow-up
Authors: Jiangtao Dr. Yu, Shaofeng Guan, Horst Huemmer, Fanzhou Cheng, László Halmàgyi, Manuela Muenzel, Thorsten Keil, Erich Duenninger
Journal: Journal of the American College of Cardiology (2015)
Mindfulness-Based Cognitive Therapy and a Group Version of the Cognitive Behavioral Analysis System of Psychotherapy for Chronic Depression: Follow-Up Data of a Randomized Controlled Trial and the Moderating Role of Childhood Adversities
Authors: Johannes Michalak, Thomas Probst, Thomas Heidenreich, Nicolai Bissantz, Elisabeth Schramm
Journal: Psychotherapy and Psychosomatics (2016)
Analysis of Bone Marrow Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib.
Authors: Concetta Quintarelli, Biagio De Angelis, Santa Errichiello, Simona Caruso, Nicola Esposito, Luigia Luciano, Simona Paratore, Claudia Galimberti, Simona Soverini, Carolina Terragna, Daniela Cilloni, Giuseppe Saglio, Giovanni Martinelli, Frank Giles, Andreas Hochhaus, Fabrizio Pane
Journal: Blood (2012)
TCT-154 Patient and Healthcare System Benefits of Contemporary Transcatheter Aortic Valve Implantation (TAVI) Practice
Authors: Neil Ruparelia, Azeem Latib, Francesco Giannini, Filippo Figini, Nicola Buzzatti, Antonio Mangieri, Damiano Regazzoli, Stefano Stella, Alessandro Sticchi, Eustachio Agricola, Michele De Bonis, Fabrizio Monaco, Pietro Spagnolo, Alaide Chieffo, Matteo Montorfano, Ottavio Alfieri, Antonio Colombo
Journal: Journal of the American College of Cardiology (2015)